View Wall Street Journal Article on Rogosin's Cancer Macrobead Research

Unique Cancer Treatment

See the latest from our cancer and diabetes program

Investigators at The Rogosin Institute have discovered and are testing a unique means of treating cancer that is based on the principle that all living cells are under feedback control for their growth and development. Over the past ten years, research at The Institute has resulted in the finding that encapsulated cancer cells (macrobeads) release substances telling freely growing cancer cells outside the macrobead to slow or stop their growth. This effect is neither tumor type- nor species-specific so that, for example, mouse cells can be used to treat human tumors and human tumor cells can be used in mouse tumors. Importantly, this means that cancer treatment can potentially be biological in nature, i.e., make use of normal biological mechanisms, and thus help avoid the toxicities associated with traditional chemotherapeutic and targeted molecular biological approaches.

To date, the cancer macrobeads have been extensively tested in the laboratory. They have also been used to treat naturally-occurring, treatment-resistant cancers in veterinary patients with very encouraging results that have included slowed growth or, in some cases, the elimination of the tumors and restoration of a normal lifespan.

Clinical Trials for cancer treatment

For description of clinical trial for cancer treatment please refer to:
Clinical Trials-Cancer
Intraabdominal cancers (various types)
Pancreatic or colorectal cancer
Prostate cancer

Collaborations

The cancer macrobead research and clinical trials for cancer are being carried out both in New York (The Rogosin Institute and NewYork-Presbyterian/Weill Cornell Medical Center) and at The Rogosin Instiute - Xenia Division in Ohio. Collaboration with scientists and physicians at other institutions including The Rockefeller University. Columbia University, The Ohio State University, the Gerald Murphy Cancer Foundation, and the Animal Cancer Foundation have played (and continue to play), an important part in this effort.

For further information about clinical trials for cancer, please contact:
Barry H. Smith MD, PhD
The Rogosin Institute
212-746-1552